ALEC

Business Context and Reporting Period

Alector, Inc. is a late-stage clinical biotechnology company focused on developing therapies for neurodegenerative diseases, specifically targeting frontotemporal dementia (FTD), Alzheimer's disease (AD), and Parkinson's disease (PD). The company utilizes a proprietary platform, Alector Brain Carrier (ABC), to enhance blood-brain barrier transport. This filing covers the fiscal year ended December 31, 2024.

Key Financial Metrics

Note: The company has no product sales revenue. Revenue is derived from collaboration agreements with GSK and AbbVie.

Material Changes vs. Prior Period

• Revenue Increase: Collaboration revenue increased by $3.5 million (3.6%) primarily due to higher recognition for the AL002 and latozinemab programs, partially offset by a decrease in AL101 revenue recognition.
• Expense Reduction: R&D expenses decreased by $6.2 million due to strategic prioritization of programs following the termination of the AL002 long-term extension study. G&A expenses increased by $2.9 million, largely driven by a $2.2 million impairment charge related to the Newark, California facility transition.
• Collaboration Termination: In January 2025, AbbVie terminated the TREM2 collaboration program (AL002) following the failure of the INVOKE-2 Phase 2 trial to meet its primary endpoint. This resulted in the termination of the AbbVie Agreement.
• Debt Financing: In November 2024, the company entered into a loan agreement for up to $50 million in term loans. It drew down $10 million initially, incurring $9.4 million in net proceeds.
• Workforce Reduction: The company initiated a reduction in force impacting approximately 41 employees (17% of the workforce) in November 2024, with expected restructuring costs of $3.9 million.

Guidance, Outlook, and Risks

• Clinical Pipeline Status:
  • Latozinemab (AL001): In the pivotal Phase 3 INFRONT-3 trial for FTD-GRN. Enrollment completed in October 2023; topline data expected in Q4 2025.
  • AL101/GSK4527226: In the Phase 2 PROGRESS-AD trial for early Alzheimer's disease. Enrollment is ongoing, with completion expected by mid-2025.
  • Preclinical: Advancing ABC-enabled candidates (ADP037-ABC, ADP050-ABC) toward IND-enabling studies.
• Liquidity Outlook: Management anticipates that the $413.4 million in cash and marketable securities as of December 31, 2024, will provide a runway through 2026. However, this estimate is subject to assumptions regarding clinical trial costs and potential additional financing needs.
• Key Risks:
  • Clinical Failure: High risk of failure in neurodegenerative drug development; AL002 recently failed its Phase 2 primary endpoint.
  • Capital Requirements: Continued need for substantial additional financing to fund operations and clinical trials.
  • Regulatory Uncertainty: Evolving standards for neurodegenerative drug approvals and potential impacts of the Inflation Reduction Act on pricing.
  • Collaboration Dependence: Reliance on GSK for commercialization and development of key assets; GSK retains the right to terminate the agreement for convenience.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the "through 2026" runway estimate given the recent workforce reduction and potential for accelerated spending on the INFRONT-3 and PROGRESS-AD trials.
• AL002 Termination Impact: Confirm the full financial and strategic implications of the AbbVie agreement termination and the reversion of rights to Alector.
• GSK Cost Sharing: Review the specific terms of the GSK Amendment regarding the $140.5 million funding responsibility for the AL101 Phase 2 trial and how cost overruns are handled.
• Debt Covenants: Examine the covenants in the new $50 million loan agreement, particularly regarding milestones required to extend the interest-only period or access the second tranche.
• INFRONT-3 Timeline: Monitor the Q4 2025 data readout date for latozinemab, as this is the primary near-term catalyst for the company's valuation.